This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeoStem Forms Advisory Group Of Experts For Steroid Resistant Asthma

NEW YORK, Sept. 9, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, is pleased to announce that three experts at the forefront of asthma research have agreed to serve as consultant advisors to NeoStem's Regulatory T cell program. William Busse, M.D., of the University of Wisconsin, Mario Castro, M.D., M.P.H, of the Washington University in St Louis, and Prescott Woodruff, M.D., M.P.H., of the University of California, San Francisco ("UCSF"), will be collaborating with NeoStem to advise and provide support in the area of asthma research. Each of the consultants brings a breadth of experience in research to assist the Company in determining the appropriate clinical endpoints for a clinical trial in steroid resistant asthma. "We are fortunate to have some of the brightest minds in asthma research working with and advising our team," said Dr. Andrew Pecora, Chief Visionary Officer of NeoStem. "Their expertise will help our own experienced NeoStem scientists to create a robust protocol for clinical trials in the area of steroid resistant asthma."

Asthma is a serious health and economic concern that affects millions. In 2010, 18.7 million adults had asthma (1 in 12 adults) and seven million children had asthma (1 in 11 children). Asthma is also expensive, costing the United States $56 billion each year. 

The formation of this consulting group comes on the heels of a recently announced collaboration between NeoStem and the UCSF laboratories of Jeffrey Bluestone, PhD, and Qizhi Tang, PhD, to work in partnership on the development of Treg therapies for the treatment of type 1 diabetes, steroid resistant asthma and organ transplant rejection. The retention of these consultants complements the Company's commitment to the development and commercialization of immunomodulatory cellular therapeutic products for the treatment of intractable diseases involving the immune system.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.93 -0.74%
FB $117.85 -0.18%
GOOG $697.49 0.26%
TSLA $213.03 -4.30%
YHOO $36.94 2.60%


Chart of I:DJI
DOW 17,702.10 +50.84 0.29%
S&P 500 2,057.75 +6.63 0.32%
NASDAQ 4,734.8530 +9.2140 0.20%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs